Smith & Nephew plc (BVMF:S1NN34)
Brazil
· Delayed Price · Currency is BRL | Market Cap | 66.78B |
| Revenue (ttm) | 33.95B |
| Net Income (ttm) | 3.44B |
| Shares Out | n/a |
| EPS (ttm) | 3.94 |
| PE Ratio | 19.40 |
| Forward PE | 14.04 |
| Dividend | 0.77 (2.27%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 2 |
| Average Volume | 43 |
| Open | 33.80 |
| Previous Close | 34.05 |
| Day's Range | 33.80 - 33.81 |
| 52-Week Range | 33.50 - 40.88 |
| Beta | 0.74 |
| RSI | 46.56 |
| Earnings Date | Apr 30, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USDNews
A Look at Smith & Nephew PLC (SNN) After 4.0% Decline -- GF Value $31.12 vs Price $32.84
A Look at Smith & Nephew PLC (SNN) After 4.0% Decline -- GF Value $31.12 vs Price $32.84
Smith+Nephew (SNN) Reports Positive Trial Results for Cartilage Repair Implant
Smith+Nephew (SNN) Reports Positive Trial Results for Cartilage Repair Implant
Smith & Nephew Breaks Above 200-Day Moving Average - Bullish for SNN
In trading on Tuesday, shares of Smith & Nephew plc (Symbol: SNN) crossed above their 200 day moving average of $34.14, changing hands as high as $34.41 per share. Smith & Nephew plc shares are curren...
Smith & Nephew (SNN) Reports Positive Trial Results for Rotator Cuff Implant
Smith & Nephew (SNN) Reports Positive Trial Results for Rotator Cuff Implant
Smith+Nephew's REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
Results from the first-ever randomized control trial for the REGENETEN Implant in partial - thickness rotator cuff repair Smith+Nephew ((LSE:SN, NYSE: SNN), the global medical technology company, tod...
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
BlackLine, Smith & Nephew, and More Stocks See Action From Activist Investors
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed...
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase it...
Smith & Nephew Earnings Call Transcript: Q4 2025
Delivered strong FY2025 results with 5.3% revenue growth, 160 bps margin expansion, and $840M free cash flow. 2026 guidance targets 6% organic revenue growth and $1.3B trading profit, with innovation and new launches driving performance.
UK medical products maker Smith & Nephew's annual profit jumps 15.5%
British medical products maker Smith & Nephew posted a 15.5% jump in annual profit on Monday, building on the success of its turnaround plans, which delivered cost savings and boosted growth across it...
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A'TOMIC™ Nitinol Fixation System ...
Smith+Nephew signs distribution agreement with SI-BONE
Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the globa...
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder r...
UK's Smith & Nephew to buy Integrity Orthopaedics for up to $450 million
British medical products maker Smith & Nephew will buy U.S.-based Integrity Orthopaedics in a deal that could be valued at up to $450 million, the company said on Monday.
Smith & Nephew Transcript: CMD 2025
RISE strategy aims for 6%-7% organic growth and 9%-10% profit over three years, driven by innovation in sports medicine, wound care, and orthopedics. ASC expansion, new product launches like landmark knee and TESSA, and operational improvements support margin and cash flow goals.
Smith & Nephew Transcript: CMD 2025
The new RISE strategy targets 6%-7% organic growth and 9%-10% profit growth, driven by innovation, operational efficiency, and focused capital allocation. Key business units will launch differentiated products, expand into new markets, and streamline portfolios, aiming for $1 billion free cash flow and 12%-13% ROIC by 2028.
Smith & Nephew boosts 2025 cashflow forecast and unveils medium-term targets
British medical products maker Smith & Nephew raised its 2025 free cash flow forecast to around $800 million and unveiled new medium-term targets ahead of its Capital Markets Day Event on Monday.
Smith & Nephew Earnings Call Transcript: Q3 2025
Q3 saw 5% underlying revenue growth, with strong performance in sports medicine, advanced wound management, and hips, while U.S. knees remained soft. Free cash flow guidance was raised to $750 million, and full-year revenue and margin guidance were reaffirmed despite ongoing headwinds from China and reimbursement changes.
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound thera...
UFC® and Smith+Nephew announce multi-year extension of partnership
Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts or...
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound ...
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty
Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the laun...
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant an...